LOUISVILLE, Ky.--(BUSINESS WIRE)--PharMerica Corporation today responded to statements issued by the U.S. Food and Drug Administration (FDA) and K-V Pharmaceutical citing information and an analysis provided to the FDA by K-V Pharmaceutical in October 2011 regarding samples of bulk hydroxyprogesterone caproate (17P) active pharmaceutical ingredients (APIs) and compounded hydroxyprogesterone products. The data provided by K-V Pharmaceutical to the FDA, which has not been made public, allegedly reported variability in the purity and potency of both the bulk APIs and compounded 17P products that were tested. PharMerica Corporation contacted K-V Pharmaceutical and inquired as to whether any of the purportedly questionable samples provided by K-V Pharmaceutical to the FDA were obtained from PharMerica or were compounded by PharMerica. K-V Pharmaceutical refused to provide any information to PharMerica.
